Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Cardiovascular Risk in NAFLD
Author(s): Paula Luque-Linero , Jose M Guerra Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Symptomology, Outcomes and Risk Factors of Acute Coronary Syndrome Presentations without Cardiac Chest Pain: A Scoping Review
Author(s): Meriem Perona , Amanda Cooklin , Christopher Thorpe , et al Added: 1 year ago

MI/ACS
EASD 2025 Highlights: Updates on Icosapent Ethyl and Cardiometabolic Risk
Author(s): Rahul Aggarwal , Dirk Müller-Wieland Added: 1 month ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type… View more

Heart Failure

Prevention & Chronic Conditions
Cardiovascular Disease and Type 2 Diabetes
Author(s): Martin Berger , Nikolaus Marx , Katharina Marx-Schütt Added: 7 months ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Author(s): Evan A Stein Added: 1 year ago
ACC.24 — We are joined onsite by investigator, Dr Evan A Stein (Medpace Reference Laboratories, US) to discuss the findings from the LIBerate-CVD trial (NCT04797247).LIBerate-CVD investigated LDL-C reductions in a cohort of 900 patients with cardiovascular diseases and hyper-LDL-cholesterol treated with 300mg subcutaneous Lerodalcibep as compared to placebo across a 52-week treatment period… View more

Prevention & Chronic Conditions
ESC 25 Guidelines Discussion: Management of Cardiovascular Disease and Pregnancy
Author(s): Harriette Van Spall , Julie De Backer Added: 1 month ago
ESC Congress 2025 - Late-breaker host Dr Harriette Van Spall (McMaster University, CA) joins Prof Julie De Backer (University Hospital Ghent, BE) to discuss the newly released 2025 ESC Guidelines for the Management of Cardiovascular Disease in Pregnancy. Together, they highlight key updates, critical advances in maternal cardiovascular care, and evidence-based recommendations tailored for this… View more

CV Disease in Special Populations

Guidelines & Statements
Clinical Clues in Cardiovascular Disease
Author(s): Yassir Javaid , Faizel Osman , Renate B Schnabel , et al Added: 2 months ago
This six-part interview series, recorded around ESC 2025, brings together leading experts to share strategies for earlier and more accurate detection of cardiovascular disease. The discussions highlight how atypical or subtle symptoms of stroke and heart failure can delay diagnosis, and why vigilance in routine practice is critical.The series also examines sex-specific differences in cardiac… View more

CV Disease in Special Populations

Electrophysiology & Arrhythmia
Could Acute COVID-19 Infection Ignite Thrombotic Risk?
Author(s): Joshua Stolker , Philippe Gabriel Steg , Roberta Rossini , et al Added: 6 months ago

COVID-19

MI/ACS
ACC 2025: Lifetime Benefit by Control of Modifiable Risk Factors
Author(s): Christina Magnussen Added: 7 months ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global… View more

Cardiovascular Renal Metabolic
Obesity and CKD: The Dual Epidemic in Cardiovascular Health
Author(s): Christopher Henry Grant , Samira Bell Added: 3 weeks ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions